A Study to Identify Novel High Quality Methylated DNA Markers in Renal Tumors

Overview

Información sobre este estudio

Primary Aims

  1. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors.
  2. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

INCLUSION CRITERIA - Case Tissue:

  • Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma.
  • Age > 18 years old.

EXCLUSION CRITERIA - Case Tissue:

  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD).
  • The current target pathology is a recurrence.
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery.
  • Patient has received chemotherapy class drugsin the 5 years prior to surgery.
  • Patient has had any transplants prior to surgery.
  • Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X.
  • Patient has Neuphritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease.

EXCLUSION CRITERIA - Renal Control Tissue:

  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD).
  • Patient has inflammation, atypia, or hyperplasia of the parenchyma.
  • Patient has a current or past history of renal cancer.
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery.
  • Patient has received chemotherapy class drugs in the 5 years prior to surgery.
  • Patient has had any transplants prior to surgery.
  • Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X.
  • Patient has Neuphritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease.

EXCLUSION CRITERIA - Urothelial Control Tissue:

  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD).
  • Patient has inflammation, atypia, or hyperplasia of the urothelium.
  • Patient has a current or past history of urothelial cancer.
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery.
  • Patient has received chemotherapy class drugs in the 5 years prior to surgery.
  • Patient has had any transplants prior to surgery.

INCLUSION CRITERIA - Case Bloods and Urine:

  • Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma.
  • Age > 18 years old.

EXCLUSION CRITERIA - Case Bloods and Urine:

  • Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers).
  • Current target pathology is a recurrence.
  • Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection.
  • Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection.
  • Patient has had any transplants prior to plasma and urine collection.
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD).
  • Gross urinary incontinence.
  • Patient has undergone cystectomy.

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

John Cheville, M.D.

Cerrado; inscripción por invitación

¿Qué es esto? (?)
"Close"
El estudio no está abierto para todos los que cumplen con los criterios de elegibilidad, sino solamente para las personas que el equipo del estudio ha invitado a participar.

Contact information:

Grant Dubbels

(507)538-6151

Dubbels.Grant@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20405567

Mayo Clinic Footer